BRPI0911048A2 - formulações líquidas tamponadas de gdf-5 - Google Patents

formulações líquidas tamponadas de gdf-5

Info

Publication number
BRPI0911048A2
BRPI0911048A2 BRPI0911048A BRPI0911048A BRPI0911048A2 BR PI0911048 A2 BRPI0911048 A2 BR PI0911048A2 BR PI0911048 A BRPI0911048 A BR PI0911048A BR PI0911048 A BRPI0911048 A BR PI0911048A BR PI0911048 A2 BRPI0911048 A2 BR PI0911048A2
Authority
BR
Brazil
Prior art keywords
gdf
liquid formulations
buffered liquid
buffered
formulations
Prior art date
Application number
BRPI0911048A
Other languages
English (en)
Inventor
Dongling Su
Julius Lopez
Original Assignee
Atrm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atrm Llc filed Critical Atrm Llc
Publication of BRPI0911048A2 publication Critical patent/BRPI0911048A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0911048A 2008-04-14 2009-04-08 formulações líquidas tamponadas de gdf-5 BRPI0911048A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4451808P 2008-04-14 2008-04-14
PCT/US2009/039925 WO2009129101A1 (en) 2008-04-14 2009-04-08 Liquid buffered gdf-5 formulations

Publications (1)

Publication Number Publication Date
BRPI0911048A2 true BRPI0911048A2 (pt) 2015-12-29

Family

ID=40886732

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0911048A BRPI0911048A2 (pt) 2008-04-14 2009-04-08 formulações líquidas tamponadas de gdf-5

Country Status (8)

Country Link
US (1) US7947649B2 (pt)
EP (1) EP2276458A1 (pt)
JP (1) JP5599778B2 (pt)
CN (1) CN102026619A (pt)
AU (1) AU2009236459B2 (pt)
BR (1) BRPI0911048A2 (pt)
CA (1) CA2720845A1 (pt)
WO (1) WO2009129101A1 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007234612B2 (en) * 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
US8198237B2 (en) * 2007-05-15 2012-06-12 Stryker Corporation Concentrated protein preparations of bone morphogenetic proteins and methods of use thereof
US7678764B2 (en) 2007-06-29 2010-03-16 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations for use at elevated temperatures
WO2009020744A1 (en) 2007-08-07 2009-02-12 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations comprising gdf-5 in aqueous acidic solution
WO2011109415A2 (en) * 2010-03-02 2011-09-09 Amgen Inc. Reducing viscosity of pharmaceutical formulations
JP5960120B2 (ja) 2010-03-31 2016-08-02 スタビリテック リミテッド ウイルス粒子の安定化
JP5869553B2 (ja) 2010-03-31 2016-02-24 スタビリテック リミテッド ウイルス粒子、ポリペプチド又は生体材料を安定化させる添加剤
WO2012018639A2 (en) 2010-07-26 2012-02-09 Biomatrica, Inc. Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
WO2012018638A2 (en) 2010-07-26 2012-02-09 Biomatrica, Inc. Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures
US20130122066A1 (en) * 2010-07-30 2013-05-16 Biopham Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh Drug delivery devices and growth factor formulations for accelerated wound healing
GB201117233D0 (en) 2011-10-05 2011-11-16 Stabilitech Ltd Stabilisation of polypeptides
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
EP3249054A1 (en) 2012-12-20 2017-11-29 Biomatrica, INC. Formulations and methods for stabilizing pcr reagents
US20150150983A1 (en) * 2013-12-02 2015-06-04 Depuy Mitek, Llc Intra-articular Formulations and Methods for Treatment of Osteoarthritis
GB201406569D0 (en) 2014-04-11 2014-05-28 Stabilitech Ltd Vaccine compositions
ES2884256T3 (es) * 2014-06-10 2021-12-10 Biomatrica Inc Métodos y composiciones para la estabilización de ácidos nucleicos en una muestra de sangre a temperaturas ambientales
WO2015191632A1 (en) 2014-06-10 2015-12-17 Biomatrica, Inc. Stabilization of thrombocytes at ambient temperatures
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
US20160074515A1 (en) 2014-06-20 2016-03-17 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
KR102589056B1 (ko) 2015-12-08 2023-10-12 바이오매트리카 인코포레이티드 적혈구 침강 속도의 감소
GB2562241B (en) 2017-05-08 2022-04-06 Stabilitech Biopharma Ltd Vaccine compositions
US20200289621A1 (en) * 2017-09-22 2020-09-17 Asahi Kasei Pharma Corporation Teriparatide-containing liquid pharmaceutical composition having excellent stability
US11324806B2 (en) 2018-10-19 2022-05-10 Warsaw Orthopedic, Inc. Sustained delivery of a growth differentiation factor
CN116478268B (zh) * 2023-05-17 2025-04-25 重庆医科大学附属第三医院(捷尔医院） Bmp2蛋白保护液、bmp2蛋白制剂及其制备方法
CN119055588B (zh) * 2024-11-06 2025-02-18 黑龙江中桂制药有限公司 一种左卡尼汀液体制剂及制备方法

Family Cites Families (150)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2931802A (en) 1958-04-30 1960-04-05 Eastman Kodak Co Mixed esters of glucose and sucrose
US4120810A (en) 1974-10-07 1978-10-17 Palmer David A Paint remover with improved safety characteristics
ATE68524T1 (de) 1985-07-09 1991-11-15 Quadrant Bioresources Ltd Beschuetzung von proteinen und aehnlichem.
IL83003A (en) 1986-07-01 1995-07-31 Genetics Inst Osteoinductive factors
US5013649A (en) 1986-07-01 1991-05-07 Genetics Institute, Inc. DNA sequences encoding osteoinductive products
US5266683A (en) 1988-04-08 1993-11-30 Stryker Corporation Osteogenic proteins
US5011691A (en) 1988-08-15 1991-04-30 Stryker Corporation Osteogenic devices
US4892319A (en) * 1988-07-20 1990-01-09 Johnson Ii Theodore D Word game
US5202311A (en) 1988-08-19 1993-04-13 Children's Medical Center Corporation Stabilized fgf composition
US5284756A (en) 1988-10-11 1994-02-08 Lynn Grinna Heterodimeric osteogenic factor
USRE38385E1 (en) 1989-02-16 2004-01-13 Nektar Therapeutics Storage of materials
ES2113857T3 (es) 1989-03-28 1998-05-16 Genetics Inst Composiciones osteoinductoras.
DE69132823T2 (de) 1990-05-16 2002-07-18 Genetics Institute, Inc. Knochen- und knorpel-bildung hervorrufende proteine
DE69131580T2 (de) 1990-06-15 2000-01-13 Carnegie Institution Of Washington, Washington GDF-1 und UOG1 Proteine
US5231169A (en) 1990-10-17 1993-07-27 Norian Corporation Mineralized collagen
US5318898A (en) 1991-04-02 1994-06-07 Genetics Institute, Inc. Production of recombinant bone-inducing proteins
US6287816B1 (en) 1991-06-25 2001-09-11 Genetics Institute, Inc. BMP-9 compositions
DE69233022T2 (de) 1991-11-04 2004-02-12 Genetics Institute, LLC, Cambridge Rekombinante knochenmorphogenetische protein heterodimere, zusammensetzungen und verfahren zur verwendung
US6171584B1 (en) 1992-02-12 2001-01-09 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh Method of treatment with growth/differentiation factors of the TGF-β family
HU218845B (hu) 1992-02-12 2000-12-28 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh. Új növekedési/differenciáló faktorokat kódoló DNS-szekvenciák, e faktorokat tartalmazó gyógyszerkészítmények, DNS-molekulák, gazdaszervezetek, antitestek, diagnosztikai eljárások
EP0672064A1 (en) 1992-11-03 1995-09-20 Creative Biomolecules, Inc. Op-3-induced morphogenesis
CA2153653C (en) 1993-01-12 2010-12-07 Se-Jin Lee Growth differentiation factor-9
EP1475440A3 (en) 1993-01-12 2004-11-17 The Johns Hopkins University School Of Medicine Growth differentiation factor-3
EP0690871A4 (en) 1993-01-12 1999-10-20 Univ Johns Hopkins Med GROWTH DIFFERENTIATION FACTOR-5
JP3698721B2 (ja) 1993-02-23 2005-09-21 ジェネンテク・インコーポレイテッド 有機溶媒を用いて処理したポリペプチドの賦形剤安定化
ES2201076T3 (es) 1993-03-19 2004-03-16 The Johns Hopkins University School Of Medicine Factor-8 de diferenciacion del crecimiento.
DK0698094T3 (da) 1993-05-12 2004-05-03 Inst Genetics Llc BMP-11-sammensætninger
DE69433742T2 (de) 1993-05-12 2005-07-07 Genetics Institute, LLC, Cambridge Bmp-10 zusammensetzungen
CA2165776A1 (en) 1993-07-09 1995-01-19 The Johns Hopkins University School Of Medicine Growth differentiation factor-6
IL110589A0 (en) 1993-08-10 1994-11-11 Bioph Biotech Entw Pharm Gmbh Growth/differentiation factor of the TGF- beta family
US6764994B1 (en) 1993-08-10 2004-07-20 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh Growth/differential factor of the TGF-B family
US5385887A (en) * 1993-09-10 1995-01-31 Genetics Institute, Inc. Formulations for delivery of osteogenic proteins
CA2171546A1 (en) 1993-10-08 1995-04-20 The Johns Hopkins University School Of Medicine Growth differentiation factor-10
DE4334646C1 (de) 1993-10-12 1994-09-29 Quinting Friedhelm Durchsichtige Analog-Zeituhr
DE69434651T2 (de) 1993-12-07 2007-03-08 Genetics Institute, Inc., Cambridge Bmp-12, bmp-13 und diese enthaltende sehne-induzierende zusammensetzungen
US5955448A (en) 1994-08-19 1999-09-21 Quadrant Holdings Cambridge Limited Method for stabilization of biological substances during drying and subsequent storage and compositions thereof
US5516645A (en) * 1994-04-25 1996-05-14 Johnson & Johnson Clinical Diagnostics, Inc. Immunoassay analytical elements containing vanadium IV(V+4)ions
IL114397A0 (en) 1994-07-01 1995-10-31 Bioph Biotech Entw Pharm Gmbh Growth/differentiation factor of the TGF-beta-family
WO1996001845A1 (en) 1994-07-08 1996-01-25 The Johns Hopkins University School Of Medicine Growth differentiation factor-11
WO1996014335A1 (en) 1994-11-07 1996-05-17 The Government Of The United States Of America, Asrepresented By The Secretary, Department Of Health And Human Services Cartilage-derived morphogenetic proteins
US6165981A (en) 1995-03-07 2000-12-26 Dade Behring Inc. Stabilizing solutions for proteins and peptides
US7235527B2 (en) 1995-04-19 2007-06-26 Biopharm Gesellschaft Zur Biotechnologieschen Entwicklung Von Pharmaka Mbh Protein and process for producing the same
GB9508691D0 (en) 1995-04-28 1995-06-14 Pafra Ltd Stable compositions
US5635372A (en) 1995-05-18 1997-06-03 Genetics Institute, Inc. BMP-15 compositions
DE69629294T2 (de) 1995-06-05 2004-04-29 Genetics Institute, LLC, Cambridge Verwendung von knochenmorphogeneseproteinen zur heilung und reparatur von bindegewebebefestigung
US5968542A (en) 1995-06-07 1999-10-19 Southern Biosystems, Inc. High viscosity liquid controlled delivery system as a device
US7833543B2 (en) 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
US5747058A (en) 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
DE69602305T2 (de) * 1995-06-09 1999-11-04 Nippon Shokubai Co. Ltd., Osaka Polycarboxylmonomer, Polymer daraus, und dieses Polymer enthaltende reinigende Zusammensetzung
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US5776193A (en) 1995-10-16 1998-07-07 Orquest, Inc. Bone grafting matrix
US5770700A (en) 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
AU2063197A (en) 1996-03-04 1997-09-22 Massachusetts Institute Of Technology Materials and methods for enhancing cellular internalization
DE69723429T3 (de) * 1996-03-22 2007-09-20 Curis, Inc., Cambridge Verfahren zur verbesserten funktionellen Erholung der motorischen Koordination, der Sprache oder Sinneswahrnehmung nach Trauma oder Ischämie des ZNS
ZA9711580B (en) 1996-12-25 1999-09-23 Hoechst Marion Roussel Ltd Process for the production of purified dimeric bone morphogenetic factors.
US5866165A (en) 1997-01-15 1999-02-02 Orquest, Inc. Collagen-polysaccharide matrix for bone and cartilage repair
US20040132653A1 (en) 1997-01-30 2004-07-08 Biopharm Gmbh Lyophilized composition of bone morphogenetic factor human MP52
EP1350525A3 (en) 1997-02-07 2003-12-10 Stryker Corporation Matrix-free osteogenic devices, implants and methods thereof
US7041641B2 (en) 1997-03-20 2006-05-09 Stryker Corporation Osteogenic devices and methods of use thereof for repair of endochondral bone and osteochondral defects
US6051558A (en) 1997-05-28 2000-04-18 Southern Biosystems, Inc. Compositions suitable for controlled release of the hormone GnRH and its analogs
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6936582B1 (en) 1997-09-09 2005-08-30 Curis, Inc. Synergistic effects of OP/BMP morphogens and GDNF/NGF neurotrophic factors
US6541606B2 (en) 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
JP4221078B2 (ja) 1998-07-09 2009-02-12 株式会社林原生物化学研究所 トレハロース２含水結晶とその製造方法並びに用途
US6207718B1 (en) 1998-08-07 2001-03-27 Ontogeny, Inc. Pharmaceutical compositions containing hedgehog protein
US7572440B2 (en) 1999-07-30 2009-08-11 Stryker Corporation Method for repairing a defect in an intervertebral disc
US6958149B2 (en) 1998-10-06 2005-10-25 Stryker Corporation Repair of larynx, trachea, and other fibrocartilaginous tissues
US6727224B1 (en) 1999-02-01 2004-04-27 Genetics Institute, Llc. Methods and compositions for healing and repair of articular cartilage
US6969404B2 (en) 1999-10-08 2005-11-29 Ferree Bret A Annulus fibrosis augmentation methods and apparatus
US6340369B1 (en) 1999-08-13 2002-01-22 Bret A. Ferree Treating degenerative disc disease with harvested disc cells and analogues of the extracellular matrix
US6419702B1 (en) 1999-08-13 2002-07-16 Bret A. Ferree Treating degenerative disc disease through transplantation of the nucleus pulposis
US6288043B1 (en) * 1999-06-18 2001-09-11 Orquest, Inc. Injectable hyaluronate-sulfated polysaccharide conjugates
US6352557B1 (en) 1999-08-13 2002-03-05 Bret A. Ferree Treating degenerative disc disease through transplantion of extracellular nucleus pulposus matrix and autograft nucleus pulposus cells
US6454804B1 (en) 1999-10-08 2002-09-24 Bret A. Ferree Engineered tissue annulus fibrosis augmentation methods and apparatus
US7435260B2 (en) 1999-08-13 2008-10-14 Ferree Bret A Use of morphogenetic proteins to treat human disc disease
US6648918B2 (en) 1999-08-13 2003-11-18 Bret A. Ferree Treating degenerative disc disease through the transplantation of dehydrated tissue
US6685695B2 (en) 1999-08-13 2004-02-03 Bret A. Ferree Method and apparatus for providing nutrition to intervertebral disc tissue
US6755863B2 (en) 1999-10-08 2004-06-29 Bret A. Ferree Rotator cuff repair using engineered tissues
US6793677B2 (en) 1999-08-13 2004-09-21 Bret A. Ferree Method of providing cells and other biologic materials for transplantation
US6344058B1 (en) 1999-08-13 2002-02-05 Bret A. Ferree Treating degenerative disc disease through transplantation of allograft disc and vertebral endplates
US6645247B2 (en) 1999-10-08 2003-11-11 Bret A. Ferree Supplementing engineered annulus tissues with autograft of allograft tendons
US6648920B2 (en) 1999-10-08 2003-11-18 Bret A. Ferree Natural and synthetic supplements to engineered annulus and disc tissues
US20030026788A1 (en) 1999-10-08 2003-02-06 Ferree Bret A. Use of extracellular matrix tissue to preserve cultured cell phenotype
US6648919B2 (en) 1999-10-14 2003-11-18 Bret A. Ferree Transplantation of engineered meniscus tissue to the intervertebral disc
JP4672947B2 (ja) 1999-12-06 2011-04-20 ウォーソー・オーソペディック・インコーポレーテッド 椎間板の治療装置及び方法
ATE309822T1 (de) 2000-04-19 2005-12-15 Genentech Inc Formulierungen mit verzögerter freisetzung enthaltend wachstumshormon
US6656492B2 (en) 2000-06-30 2003-12-02 Yamanouchi Pharmaceutical Co., Ltd. Quick disintegrating tablet in buccal cavity and manufacturing method thereof
US20030185812A1 (en) 2000-06-30 2003-10-02 Ferree Bret A. Method of treating dural leaks with platelet-rich plasma (PRP)
US20020032155A1 (en) 2000-06-30 2002-03-14 Ferree Bret A. Method of treating disc herniation and disc degeneration with concentrated growth and differentiation factors
US20020173770A1 (en) 2001-05-16 2002-11-21 Flory Alan R. Adhesive delivery system
AU2002320122B2 (en) 2001-06-21 2007-07-26 Genentech, Inc. Sustained release formulation
EP1450838A4 (en) 2001-10-05 2005-09-28 Intermune Inc METHOD FOR THE TREATMENT OF HEPATITIS INFECTIONS WITH A MULTIPHASIC INTERFERON DELIVERY PROFILE
US20060024346A1 (en) 2004-07-29 2006-02-02 Brody Richard S Stabilization of biologically active proteins with mixtures of polysaccharides and amino acid based compounds
SI1448246T2 (sl) * 2001-11-19 2015-12-31 Scil Technology Gmbh Postopek za proizvodnjo homogeno obložene naprave, ki ima osteoinduktivne in osteokonduktivne lastnosti
TWI265654B (en) 2001-11-21 2006-11-01 Polyfuel Inc Catalyst agglomerates for membrane electrode assemblies
WO2003066120A1 (en) 2002-02-04 2003-08-14 Ferree Bret A Treating degenerative disc disease through transplantation of allograft disc
NZ535008A (en) 2002-02-08 2005-09-30 Alkermes Inc Polymer-based compositions for sustained release
US6780324B2 (en) 2002-03-18 2004-08-24 Labopharm, Inc. Preparation of sterile stabilized nanodispersions
US20030192554A1 (en) 2002-04-11 2003-10-16 Ferree Bret A. Methods and apparatus for adhering musculoskeletal tissues
US6981991B2 (en) 2002-06-27 2006-01-03 Ferree Bret A Arthroplasty devices configured to reduce shear stress
US20040022771A1 (en) 2002-07-30 2004-02-05 Ferree Bret A. Transfer of cells, tissue, and other substances to bone
US7744651B2 (en) 2002-09-18 2010-06-29 Warsaw Orthopedic, Inc Compositions and methods for treating intervertebral discs with collagen-based materials
WO2004037265A1 (en) 2002-10-25 2004-05-06 Akzo Nobel N.V. Prolonged release pharmaceutical composition
EP1462126A1 (en) * 2003-03-28 2004-09-29 BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH Improved Osteoinductive Materials
AU2004229335C1 (en) 2003-04-04 2010-06-17 Genentech, Inc. High concentration antibody and protein formulations
DE10333835A1 (de) 2003-07-24 2005-03-10 Gruenenthal Gmbh 6-Dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol enthaltendes Arzneimittel mit verzögerter Wirkstofffreisetzung
US7375077B2 (en) 2003-09-19 2008-05-20 The Board Of Trustees Of The University Of Illinois In vivo synthesis of connective tissues
US7879102B2 (en) 2003-09-30 2011-02-01 Depuy Acromed, Inc. Method for treatment of defects in the intervertebral disc
WO2005065079A2 (en) 2003-11-10 2005-07-21 Angiotech International Ag Medical implants and fibrosis-inducing agents
SI21639A (sl) 2003-12-23 2005-06-30 LEK farmacevtska dru�ba d.d. Farmacevtski pripravek, ki vsebuje nemicelarne sulfobetaine
KR20070010046A (ko) 2004-04-06 2007-01-19 제넨테크, 인크. Ｄｒ5 항체 및 그의 용도
US20070269477A1 (en) 2004-05-05 2007-11-22 Igo Stephen R Heart Treatment Method
ES2369629T3 (es) 2004-05-25 2011-12-02 Stryker Corporation Uso de op-1 para tratar defectos del cartílago.
EP1604693A1 (en) 2004-06-09 2005-12-14 Scil Technology GmbH In situ forming scaffold, its manufacturing and use
FR2871457B1 (fr) 2004-06-10 2006-08-11 Giat Ind Sa Composition pyrotechnique ayant une tenue mecanique amelioree
US8105983B2 (en) 2005-03-29 2012-01-31 The Regents Of The University Of California High-throughput method for optimum solubility screening for homogeneity and crystallization of proteins
WO2006138181A2 (en) 2005-06-14 2006-12-28 Amgen Inc. Self-buffering protein formulations
US20060287676A1 (en) 2005-06-15 2006-12-21 Rita Prajapati Method of intra-operative coating therapeutic agents onto sutures, composite sutures and methods of use
US20060286289A1 (en) 2005-06-15 2006-12-21 Rita Prajapati Method of intraoperative coating therapeutic agents onto sutures
US20060286171A1 (en) 2005-06-17 2006-12-21 Tianhong Zhou Bone morphogenetic protein formulations
US7648764B2 (en) * 2005-06-30 2010-01-19 Uchicago Argonne, Llc Two-piece container seal and method of manufacture
AU2006295340B2 (en) 2005-08-05 2010-11-11 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
US8932633B2 (en) 2005-08-29 2015-01-13 Biopharm Solutions Inc. Polysaccharide microparticles containing biological agents: their preparation and applications
EP1954344B1 (en) 2005-08-31 2017-05-31 Cochlear Limited Elongate implantable carrier member having a stiffener
CN101365499A (zh) 2005-11-01 2009-02-11 骨骼技术股份有限公司 骨基质组合物和方法
JP5405122B2 (ja) 2005-12-21 2014-02-05 ワイス・エルエルシー 低粘度のタンパク質製剤およびその用途
US20070178159A1 (en) 2006-01-30 2007-08-02 Alza Corporation In-Situ Forming Porous Scaffold
EP1880731A1 (en) 2006-07-18 2008-01-23 BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH Human growth and differentiation factor GDF-5
US20080098614A1 (en) 2006-10-03 2008-05-01 Wyeth Lyophilization methods and apparatuses
ES2432395T3 (es) 2006-10-12 2013-12-03 Ethicon, Inc. Células derivadas de riñon y metodo de uso en la reparación y regeneración tisular
EP1915986A1 (en) 2006-10-23 2008-04-30 BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH Lipid growth factor formulations
AU2007234612B2 (en) 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
US8048857B2 (en) 2006-12-19 2011-11-01 Warsaw Orthopedic, Inc. Flowable carrier compositions and methods of use
US20100184659A1 (en) 2006-12-21 2010-07-22 Warren Jaworowicz Sustained-Release Formulations Comprising Crystals, Macromolecular Gels, and Particulate Suspensions of Biologic Agents
GB2446652A (en) 2007-02-16 2008-08-20 Inion Ltd Osteogenic compounds
GB2446653A (en) 2007-02-16 2008-08-20 Inion Ltd Osteogenic compounds
US20080234727A1 (en) 2007-03-22 2008-09-25 Venkat Garigapati Novel Carriers For Coating Growth Factors Onto Sutures
US8198237B2 (en) 2007-05-15 2012-06-12 Stryker Corporation Concentrated protein preparations of bone morphogenetic proteins and methods of use thereof
US7883664B2 (en) 2007-06-27 2011-02-08 University Of North Carolina At Charlotte Microwave drying process for vitrification of biologics
US7678764B2 (en) 2007-06-29 2010-03-16 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations for use at elevated temperatures
DE602008004351D1 (de) * 2007-06-29 2011-02-17 Atrm Llc Flüssige proteinformulierungen mit gdf-5 zur verwendung bei erhöhten temperaturen
WO2009006301A2 (en) 2007-06-29 2009-01-08 Battelle Memorial Institute Protein stabilization
FR2919188B1 (fr) 2007-07-27 2010-02-26 Proteins & Peptides Man Complexes entre un polymere amphiphile et une proteine osteogenique appartenant a la famille des bmps
EP2019117A1 (en) 2007-07-27 2009-01-28 BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH Optimized purification process of recombinant growth factor protein
GB2451451A (en) 2007-07-30 2009-02-04 Inion Ltd Osteogenic compounds
WO2009020744A1 (en) 2007-08-07 2009-02-12 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations comprising gdf-5 in aqueous acidic solution
KR20210049186A (ko) 2007-11-30 2021-05-04 애브비 바이오테크놀로지 리미티드 단백질 제형 및 이의 제조방법
WO2009140162A1 (en) 2008-05-15 2009-11-19 Baxter International Inc. Stable pharmaceutical formulations
ES2968301T3 (es) 2008-08-05 2024-05-08 Wyeth Llc Liofilización por encima del colapso

Also Published As

Publication number Publication date
JP5599778B2 (ja) 2014-10-01
EP2276458A1 (en) 2011-01-26
JP2011516608A (ja) 2011-05-26
CA2720845A1 (en) 2009-10-22
US20090259023A1 (en) 2009-10-15
AU2009236459B2 (en) 2013-07-25
WO2009129101A1 (en) 2009-10-22
CN102026619A (zh) 2011-04-20
AU2009236459A1 (en) 2009-10-22
US7947649B2 (en) 2011-05-24

Similar Documents

Publication Publication Date Title
BRPI0910515A2 (pt) composição líquida
BRPI0921298A2 (pt) dispositivo de exibição
BRPI0822306A2 (pt) Dispositivo de exibição
BRPI0818324A2 (pt) formulações líquidas de lh
BRPI0909644A2 (pt) dispositivo de foto-epilação
PT3072906T (pt) Formulação de anticorpos
EP2248011A4 (en) ROUTE REWARD INCREASE
BRPI0912271A2 (pt) co-autoria estruturada
BRPI0909375A2 (pt) Moduladores de receptores de quimiocinas
EP2334277A4 (en) CRUTCH
DK2114143T3 (da) Flydende sulfonylurea-herbicidformuleringer
DK2200752T3 (da) Doseringsindretning
BRPI0913252A2 (pt) dispositivo de display
EP2504020A4 (en) Daptomycin FORMULATIONS
EP2383711A4 (en) DRIVER ASSISTANCE DEVICE
BRPI0906734A2 (pt) Dispositivo de virola
BRPI0915210A2 (pt) dispositivo de exibição
DK2323933T3 (da) Stableenhed
DK2342060T3 (da) Doseringsindretning
BRPI0923891A2 (pt) dispositivo de dosagem
BRPI0918475A2 (pt) dispositivo de display
DE112009002275A5 (de) Anzeigevorrichtung
ATE520307T1 (de) Stabilisierte malathion-mikrokapselformulierungen
BRPI0915364A2 (pt) dispositivo de visualização
PT2376075E (pt) Formulações nasais de metoclopramida

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]